NEW YORK, May 21 (Reuters) - Cigna CI.N said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more than $200 a month out-of-pocket for weight-loss drugs Wegovy and Zepbound.
Cigna's pricing compares to the cash-pay market for weight-loss drugs, said Harold Carter, a senior vice president at Evernorth.
(Reporting by Amina Niasse; editing by Caroline Humer)
((amina.niasse@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。